Chimeron has developed a novel nanoparticle technology platform called ChaESAR (chimera-encased self-amplifying RNA) that harnesses the properties of self-amplifying RNA (saRNA) and synthetic ...

A significant breakthrough in RNA therapeutics, this self-amplifying technology overcomes key challenges by incorporating alternative chemical building blocks. Detailed in a Nature Biotechnology ...

Synthetic RNA platforms allow for rapid ... to individual treatments or rapidly emerging disease outbreaks. Self-amplifying RNAs have shown enhanced antigen expression at lower doses compared ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

A year after bursting onto the scene amid the RNA renaissance, scientific challenges and regulatory resistance have held back ...

In a paper published today (August 15) in PNAS, scientists from the Scripps Research Institute in La Jolla, California, report on their use of in vitro evolution to generate an improved polymerase ...

Keylicon Biosciences is a biotechnology company dedicated to developing innovative RNA-based therapeutics. With a focus on self-amplifying RNA technology, Keylicon strives to create safer ...

including circular RNA, self-amplifying RNA and beyond from discovery to clinic and towards scalable manufacturing, unlocking the huge therapeutic and commercial potential of this emerging class ...

a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION™) technologies for use in malaria ...